Clinical Trial Update: A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Axatilimab alone or in combination with Durvalumab in patients with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors
• Unresectable Cancer

Drugs mentioned

• Axatilimab (axatilimab)
• Durvalumab (durvalumab)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Solid Tumor, Metastatic Tumor | Phase 1 | Status: COMPLETED